2020
Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy
Guo F, Song X, Li Y, Guan W, Pan W, Yu W, Li T, Hsieh E. Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy. Osteoporosis International 2020, 32: 321-332. PMID: 32803316, PMCID: PMC9509525, DOI: 10.1007/s00198-020-05584-w.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAsiaBone DensityChinaHIV InfectionsHumansMaleMiddle AgedRetrospective StudiesConceptsTenofovir disoproxil fumarateLong-term clinical managementBone mineral density lossMineral density lossAntiretroviral therapyDisoproxil fumarateClinical managementRisk factorsGreater bone mineral density lossInitiation of TDFDual-energy x-ray absorptiometry testingHIV-specific parametersNon-TDF groupUndetectable viral loadOutpatient HIV clinicRelated risk factorsLarge tertiary hospitalBone mineral densityDensity lossAntiretroviral initiationTDF groupWeek 96HIV clinicWeek 48HIV diagnosis
2018
Continued Interest and Controversy: Vitamin D in HIV
Hsieh E, Yin MT. Continued Interest and Controversy: Vitamin D in HIV. Current HIV/AIDS Reports 2018, 15: 199-211. PMID: 29713871, PMCID: PMC6003869, DOI: 10.1007/s11904-018-0401-4.BooksMeSH KeywordsAnti-HIV AgentsBone DensityDietary SupplementsFemaleHIVHIV InfectionsHumansMaleRiskTenofovirVitamin DVitamin D DeficiencyConceptsVitD deficiencyVitD supplementationExtra-skeletal outcomesSetting of HIVSubgroup of HIVBone mineral densityRecent FindingsRecent studiesART regimensD deficiencyClinical outcomesPoor outcomeSummaryFurther researchVitamin DChronic diseasesClinical trialsDifferent demographic strataMineral densityClinical roleHIVGreater riskDemographic strataSignificant heterogeneityOutcomesRiskSupplementation
2017
Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease
Guo F, Hsieh E, Lv W, Han Y, Xie J, Li Y, Song X, Li T. Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease. BMC Infectious Diseases 2017, 17: 287. PMID: 28427339, PMCID: PMC5397830, DOI: 10.1186/s12879-017-2358-0.Peer-Reviewed Original ResearchConceptsCVD risk factorsFramingham risk scoreRisk factorsRisk scoreCVD riskAtherosclerotic cardiovascular disease risk scoreCommon CVD risk factorsCardiovascular disease risk scoreAdvanced HIV diseaseD risk scoreTreatment-naïve HIVLipid-lowering therapyPrevalence of hypertensionRisk factor treatmentBurden of CVDCardiovascular disease riskTreatment-naïve individualsMulticenter clinical trialAntiretroviral-naïve adultsDisease risk scoreRoutine clinical assessmentHIV providersAdverse eventsBackgroundCardiovascular diseaseHIV disease
2016
Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV
Hsieh E, Fraenkel L, Han Y, Xia W, Insogna KL, Yin MT, Zhu T, Cheng X, Li T. Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV. AIDS 2016, 30: 1935-1942. PMID: 27124896, PMCID: PMC4949136, DOI: 10.1097/qad.0000000000001131.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumarateVitamin DProcollagen type 1 N-terminal propeptideInitiation of TDFTenofovir/lamivudine/efavirenzVitamin D binding protein (VDBP) levelsCollagen type 1 cross-linked C-telopeptideIntact parathyroid hormone levelsCross-linked C-telopeptideIntact parathyroid hormoneParathyroid hormone levelsTotal procollagen type 1 N-terminal propeptideBinding protein levelsProtein levelsMulticenter clinical trialPlasma samplesOngoing multicenter clinical trialsN-terminal propeptideClinical characteristicsParathyroid hormoneBone lossFormation markersDisoproxil fumarateC-telopeptideBone resorption
2014
Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV
Hsieh E, Fraenkel L, Xia W, Hu YY, Han Y, Insogna K, Yin MT, Xie J, Zhu T, Li T. Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV. Osteoporosis International 2014, 26: 1035-1044. PMID: 25224293, PMCID: PMC4334679, DOI: 10.1007/s00198-014-2874-3.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusLopinavir/ritonavirBone turnover markersBone resorption marker levelsResorption marker levelsNon-Chinese populationsAntiretroviral therapyTreatment failureImmunodeficiency virusMarker levelsSkeletal metabolismC-terminal cross-linking telopeptideLopinavir/ritonavir therapyTreatment-naïve patientsFirst-line therapyBone resorption markersProcollagen type 1Multi-center trialPlasma samplesChinese individualsN-terminal propeptideType 1 collagenRitonavir therapyTurnover markersResorption markers
2001
Clinical Care Issues for Women Living with HIV and AIDS in the United States
Marlink R, Kao H, Hsieh E. Clinical Care Issues for Women Living with HIV and AIDS in the United States. AIDS Research And Human Retroviruses 2001, 17: 1-33. PMID: 11177380, DOI: 10.1089/088922201750056753.BooksConceptsEffects of HIVSex-specific researchNew antiviral agentsClinical care issuesGynecological complicationsHIV infectionGynecological issuesSex-specific differencesClinical careHIVAntiviral agentsAppropriate careWomen's susceptibilityNumber of casesPsychiatric stressNumber of womenCare issuesAdverse effectsWomenMedical communityAIDSComplicationsUnited StatesTransmission accountsCare